Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
- 4 June 2024
- journal article
- research article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (10) , e350-e358.e1
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- CAR T-Cell Therapy in the Older Person: Indications and RisksCurrent Oncology Reports, 2022
- Multi‐center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab eraAmerican Journal of Hematology, 2021
- Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective StudyClinical Therapeutics, 2021
- A medicare database analysis of practice patterns in patients with mantle cell lymphomaJournal of Geriatric Oncology, 2021
- Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinibAmerican Journal of Hematology, 2021
- Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experienceCancer Medicine, 2019
- Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United StatesCancer Medicine, 2019
- Ibrutinib-Associated Atrial FibrillationJACC: Clinical Electrophysiology, 2018
- Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 studyThe Lancet, 2016
- Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004Cancer, 2008